Provided by Tiger Fintech (Singapore) Pte. Ltd.

89Bio, Inc.

8.79
+0.24002.81%
Post-market: 8.72-0.0699-0.80%16:13 EDT
Volume:1.38M
Turnover:12.06M
Market Cap:1.28B
PE:-2.51
High:9.00
Open:8.45
Low:8.33
Close:8.55
Loading ...

Company Profile

Company Name:
89Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
93
Office Location:
142 Sansome Street,Second Floor,San Francisco,California,United States
Zip Code:
94104
Fax:
- -
Introduction:
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Directors

Name
Position
Rohan Palekar
Chief Executive Officer and Director
Anat Naschitz
Director
Derek Paul Di Rocco
Director
Gregory Grunberg
Director
Michael Hayden
Director

Shareholders

Name
Position
Rohan Palekar
Chief Executive Officer and Director
Ram Waisbourd
Chief Operating Officer and Chief Business Officer
Ryan Martins
Chief Financial Officer
Hank Mansbach
Chief Medical Officer
Quoc Le Nguyen
Chief Technical Operations Officer and Head of Quality